We sought to determine the efficacy of high-dose liraglutide (3.0 mg once daily) in patients with prior bariatric surgery.
EMA’s safety committee, the PRAC, is reviewing data on the risk of suicidal thoughts and thoughts of self-harm with medicines known as GLP-1 receptor agonists, including Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide)
Novo Nordisk has announced two separate regulatory submissions for a 3 mg dose of liraglutide, a once-daily human GLP-1 analogue,...
Results from the SCALET Obesity and Pre-diabetes phase IIIa trial will be presented on 16 May, 2014 for the first...
New data from the phase IIIa SCALE (Satiety and Clinical Adiposity: Liraglutide Evidence in Non-Diabetic and Diabetic adults) Obesity and...
Objective: Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a modifiable cardiovascular risk factor and emerging therapeutic target. Liraglutide, an analog of glucagon-like peptide-1, is indicated ...
Pooled post-hoc analysis results from the SCALE Obesity and Prediabetes, and SCALE Diabetes trials demonstrated that at 56 weeks, people...
Novo Nordisk has announced that the European Commission has granted marketing authorisation for Saxenda (liraglutide 3 mg) for the treatment...
Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of • ≥ 30 kg/m 2 (obese), or • ≥ 27 kg/m 2 to <30 kg/m 2 (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.
Obesity is associated with differences in stomach function, feeling of fullness after meals, and total calories consumed at a buffet...